Canaccord analyst Whitney Ijem lowered the firm’s price target on BioMarin to $104 from $110 and keeps a Hold rating on the shares. The firm noted the FDA approved Roctavian in the US for the treatment of severe hemophilia A in adults who test negative for AAV5 antibodies. Nothing on the call changed our thinking about initial uptake, and we remain slightly below guidance at $45M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BMRN:
- 3 Best Stocks to Buy Now, 7/4/2023, According to Top Analysts
- BioMarin approval ‘should be a win’ despite ValRox label confusion, says Stifel
- BioMarin price target raised to $73 from $69 at Wedbush
- BioMarin approval sets stage for revenue doubling, says William Blair
- BioMarin launch of Roctavian to bring upside, says Barclays